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Abstract
Background: Chronic neutrophil inflammation of the respiratory tract tissues plays a key role in the
pathogenesis and in prognosis of cystic fibrosis (CF). It is evident that an anti-inflammatory therapy
represents an important step in the treatment of CF patients. Corticosteroids and ibuprofen have been
proven to slow down the impairment of the pulmonary function in CF patients but their use is limited by
the frequency of adverse events. A novel strategy for delivering low doses of steroids for long periods
through the infusion of autologous erythrocytes loaded with dexamethasone has been recently set up. A
recent study suggested the feasibility of therapy with low doses of corticosteroids delivered through
engineered erythrocytes in CF patients. This study presents a further analysis of safety and efficacy of this
therapy.
Methods: The treatment group was not randomised and the assignment was based on the patient's
consent. Patients entered the study if they had a forced expiratory volume in 1 second (FEV1) <70%,
puberty development completed, pancreatic insufficiency, and chronic pulmonary infection requiring
frequent cycles of intravenous antibiotic therapy. Patients were excluded if they underwent systemic
corticosteriod therapy in the three months preceding the experimental treatment or were on therapy
with non-steroidal anti inflammatory drugs (NASDs) ,  o r  i f  t h e y  h a d  l i v e r  C F  d i s e a s e ,  a l l e r g i c
bronchopulmonary aspergillosis, or positive tuberculin test. Controls were patients who followed a
standard treatment, who fulfilled the enrolment criteria, and who were matched to the experimental
group by gender, age, and severity of the disease.
Results: Nine patients in the experimental group received the treatment once a month for a period of 24
month. Patients did not develop diabetes, cataract, or hypertension, or other typical side effects of steroid
treatment during the follow up period. There was a constant improvement of FEV1 in patients undergoing
the experimental treatment compared to a gradual decrease of the same parameter in the standard
therapy group (P = 0.04). The average of clinic and radiological indexes did not vary. The number of
infective relapses that have required antibiotic intravenous therapy was not different in the two groups,
although the average of these episodes was slightly higher in the experimental therapy group.
Conclusion: Intraerythrocyte corticosteroid treatment may stabilize the respiratory function in CF
patients but is often considered too invasive by patients. The results obtained by our study may help
planning an experimental, controlled, randomised study. A sample size of 150 patients per group would be
sufficient for demonstrating such a difference with a 95% confidence interval and a power of 90%.
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Background
Chronic neutrophil inflammation of the respiratory tract
tissues plays a key role in the pathogenesis of cystic fybro-
sis (CF). It has been shown that CF breast-fed children
have a bronchopulmonary inflammation before the
appearance of bacterial infections [1-3]. It is therefore evi-
dent that an anti-inflammatory therapy represents an
important step in the treatment of CF patients [4].
Some authors already expressed the hope that uncertain-
ties on the use of anti-inflammatory therapy in CF
patients should have been removed [5], and new evi-
dences supporting the role of inflammation in the patho-
genesis of CF have recently been gathered [6-8].
Corticosteroids and ibuprofen have been proven to slow
down the impairment of the pulmonary function in CF
patients but their use is limited by the frequency and
severity of adverse effects [9-12].
Indeed, CF patients are often treated with corticosteroids
during pulmonary infective breakthroughs, as shown by
Oermann who reported that 41% of physicians in CF cen-
tres prescribe long-lasting oral steroids [13]. Pharmaco-
logical activity of corticosteroids varies from one patient
to another depending on drug absorption especially if
administered by aerosol. New systems for slow release of
corticosteroids which maintain therapeutic systemic con-
centrations for a prolonged time using a low quantity of
drug, would therefore be useful for the treatment of CF
patients. A novel strategy for delivering low doses of ster-
oids for long periods through the infusion of autologous
erythrocytes loaded with dexamethasone has been
recently set up [14,15]. It has been demonstrated that
encapsulated erythrocites present normal morphology,
normal metabolic and antigenic properties, and normal
survival in vivo [16]. Furthermore a pharmacokinetics
study demonstrated that consistent and persistent plasma
level can be maintained up to one month after infusion
independently of the starting amount of encapsulated
dexamethasone 21-P [17].
A recent study suggested the feasibility and a favourable
effect of therapy with low doses of corticosteroids deliv-
ered through engineered erythrocytes in CF patients up to
15 months of therapy [17]. This study extends the follow
up of these patients to 24 months and presents a further
analysis of safety and efficacy of this therapy.
Methods
Study population
Patients were enrolled at the CF Unit of the Bambino Gesù
Hospital, Rome, if they had a definite diagnosis of CF
through at least two sweat tests according to Gibson and
Cook [18], and through a research of mutation of CFTR
gene. Patients entered the study if they had a forced expir-
atory volume in 1 second (FEV1) <70%, puberty develop-
ment completed (Tanner V level stage), pancreatic
insufficiency (fat balance evaluation <93% and/or faecal
elastase <200 μg/g faeces), and chronic bacterial pulmo-
nary infection requiring frequent cycles of intravenous
antibiotic therapy. Patients were excluded if they under-
went systemic corticosteroid therapy in the three months
preceding the experimental treatment or were on therapy
with non-steroidal anti-inflammatory drugs (NSADs), if
they had liver CF disease, allergic bronchopulmonary
aspergillosis, or positive tuberculin test.
The study has been approved by the Ethics Committee of
Paediatric Hospital Bambino Gesù and all the patients (or
their parents/guardians) have signed an informed con-
sent. Two study groups were considered for this study:
individuals who underwent the experimental treatment
were compared to a group of patients who followed a
standard treatment, who fulfilled the enrolment criteria,
and who were matched to the experimental group by gen-
der, age ( ± 2 years), and severity of the disease (FEV1 at
enrolment ± 10%; Shwachman index ± 20; Crispin score
± 5) [19,20].
The treatment was not randomised and the assignment
was based on the patient's consent. 
Treatment
The experimental treatment consists in collecting 50 ml of
blood into a syringe containing heparin. Erythrocytes are
loaded with dexamethasone 21-phosphate through lysis
in a hypotonic solution, the drug is entrapped, and the
cells are resealed with the use of a "Red Cell Loader"
device [14]. Loaded red cells are then reinfused into the
original patient resulting in released quantities of dexam-
ethasone 21-phosphate ranging from 0.1 to 0.2 nmol/ml
of plasma for up to one month [17]. The entire procedure
requires two hours to be completed. Patients in the exper-
imental group received the treatment once a month for a
period of 24 months.
All patients followed standard prevention therapies, treat-
ment of chronic pulmonary infection and pancreatic
insufficiency (aerosol therapy with DNase and beclom-
ethasone, Pulmozyme, daily FKT, vitamins, pancreatic
enzymes), and received antibiotic treatment in case of
infective relapses.
Follow up and outcome
All patients underwent Bone Mineralometry (BM), ocular
tonometry, and arterial pressure measurement before
entering the trial. Clinical, bacterial, and functional respi-BMC Pediatrics 2006, 6:17 http://www.biomedcentral.com/1471-2431/6/17
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ratory data were monitored for 12 months before and in
the 24 months after starting the experimental treatment,
and for a corresponding period of time (36 months) in
patients assigned to standard treatment. Patients were
continuously monitored for the inflammatory (c-reactive
protein, erythrosedimentation rate), infective (white
blood cell count, culture of expectoration with antibio-
gram), and nutritional parameters (weight), and under-
went functional pulmonary tests (FEV1 and forced vital
capacity (FVC) at any control. All patients were invited to
be visited once a month. As for safety of treatment, we
studied the oral glucose tolerance test (every year), gly-
cated haemoglobin (every month), bone mineral density,
and ocular tonometry (at the end of the study), while
blood pressure, skin lesions, and other side effects were
monitored at each visit. We have analysed Shwachman
and Crispin indexes at the end of treatment, and FEV1
trend over time. Episodes of infective bronchopulmonary
breakthrough according to Ramsey criteria were also con-
sidered in the outcome measures [21] as well as the
number of visits performed during the study period.
Statistical analysis
Since this study was designed as a pilot trial we did not
perform any estimation of the sample size required for
showing any effect of the treatment or any difference in
the rate of side effects.
Variations in the Shwachman and Crispin indexes were
evaluated through the Student t test. We have used the
standard deviations (Z scores) of FEV1 for each visit based
on the patient average of measures during the 12 months
preceding the trial. The mean and standard deviation of
FEV1 Z scores were calculated for each time interval. A
general linear model repeated-measures ANOVA was used
to compare
FEV1 Z scores in patients with the experimental treatment
with those with standard therapy. Linear regression was
used to describe the FEV1 Z score trend over time. The
incidence density rates of infectious episodes have been
compared through the Student t test, whereas frequencies
of side effects in the two groups have been compared
through the Chi square test. Analyses were performed
with the statistical package SPSS (version 11.5, SPSS, Inc).
Results
We enrolled 17 patients in the experimental group and
nine patients in the standard treatment group. Of the 17
patients in the experimental group, eight received less
than four administrations of dexamethasone phosphate
through loaded erythrocytes and therefore were excluded
from further analyses. These patients (2 males, 6 females;
median age 23,5; SD:7 years) had similar demographic
characteristics of patients continuing the experimental
therapy and did not continue the red cell loading because
of personal discomfort in receiving the treatment, or for
difficulties in being regularly visited and treated by our
centre. None of these patients developed any side effects.
The baseline characteristics of patients are illustrated in
Table 1. The two groups showed similar demographic and
clinical characteristics at the beginning of the trial.
Two patients in the experimental treatment group, and
two in the standard treatment group had a diagnosis of
diabetes type 1 before entering the study. Six patients in
the experimental treatment group and nine in the stand-
ard treatment group received TOBI therapy during the
study.
None of the patients in the experimental treatment group
developed diabetes, while two patients in the standard
treatment group did (22%). We did not observe any
decrease of bone mineral density, or any increase of ocular
pressure in the two groups of patients. No patients devel-
oped cataract, arterial hypertension, or cutaneous striae
rubrae, and no death was observed.
Shwachman and Crispin scores did not vary in the two
groups during follow up, as indicated in Table 2. Average
FEV1 at enrolment, at 12, and 24 months are reported in
Table 3. Despite we did not observe any significant differ-
ence in the average FEV1 due to the small sample size,
these measures indicate an opposite trend in the two
groups: FEV1 tended to increase in the experimental treat-
ment group, while in the standard treatment a decreasing
trend was observed.
The analysis of FEV1 Z scores over time (Figure 1) con-
firmed opposite trends in the two groups. In the experi-
Table 1: Baseline characteristics of the patients enrolled in the trial
Erythrocyte mediated steroid therapy Ordinary therapy
No. of patients 9 9
Females, no. 5 5
Age at enrolment, years (range) 19.8 (15–26) 20.0 (13–26)
Colonization by P. aeruginosa 6 7
Colonization by B. cepacia 31
Colonization by Staphilococcus aureus -1BMC Pediatrics 2006, 6:17 http://www.biomedcentral.com/1471-2431/6/17
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mental treatment group we observed a progressive
improvement of FEV1 compared to the average FEV1
observed before starting experimental therapy. At the end
of the follow up period, FEV1 in the experimental treat-
ment group was nearly one standard deviation higher
than the reference period. On the contrary, in patients
with standard treatment we observed a progressive
decrease of FEV1 with a value at 24 months 1.5 standard
deviations less than the reference period. The differences
observed were statistically significant (P = 0.04).
Patients in the experimental treatment group underwent a
number of visits higher than the standard treatment group
during follow up (experimental treatment: 1.1 visit per
person month; standard treatment: 0.7 visit per person
month; P < 0.01). The incidence of infectious episodes
was slightly higher in patients who underwent the experi-
mental treatment (experimental treatment: 0.24 per per-
son month; standard: 0.18 per person month; P=0.08).
None of the eight patients originally enrolled in the exper-
imental therapy group who did not complete the study
died or underwent transplantation, but all of them had a
FEV1 stable or lower than measured at the beginning of
the trial compared to that measured after 24 months.
Discussion
This study provides further elements supporting that ther-
apy with dexamethasone 21-phosphate-delivered in
autologous erythrocytes may be safe and moderately effi-
cacious in CF patients.
An earlier study performed on the same patients focused
on pharmacokinetics and technical details of therapy with
dexamethasone 21-phosphate-delivered in autologous
erythrocytes [17]. In the present manuscript we reviewed
FEV1 values over time in the same patients, and pro-
longed the follow up period. The present results substan-
tially reduce the apparent effect of treatment on
functional respiratory tests previously reported. However,
the benefits associated with this therapy seem to be
extended beyond 15 months of follow up.
The availability of a safe means to administer corticoster-
oids may be advantageous for CF patients, as well as for
other diseases requiring chronic use of these drugs.
Studies performed in North America on CF patients indi-
cated that treatment with oral steroids was efficacious in
improving respiratory function but it caused several
adverse effects, such as a significant modification of glu-
cose metabolism and growth failure [10,11], particularly
after two years of treatment. In fact, the low doses of ster-
oids administered with loaded erythrocytes may reduce
these side effects. All patients included in this study com-
pleted sexual development and therefore we were not able
to measure any effect on growth. However, during the fol-
low up period no patients in the experimental group
developed diabetes, cataract, or hypertension or other typ-
ical side effects of steroid treatment such as Cushingoid
aspect or skin manifestations.
The main result of this study is a constant improvement of
FEV1 in patients undergoing the experimental treatment
compared to a gradual decrease of the same parameter in
the standard therapy group. The average clinic and radio-
logic indexes did not vary in the two groups since such
parameters are certainly less sensitive in defining the
patient's pulmonary performance in the short term.
Although the study was not randomized, the patients of
the two group at the beginning of the trial were similar for
age, gender, colonization, respiratory function, and dis-
ease stage. We did not perform an intention to treat anal-
Table 3: Variation of FEV1 during follow up
Erythrocyte mediated steroid therapy Ordinary therapy P value
FEV1 at enrolment (-12 months), average (95% CI) 53.8 (25.6–82.0) 56.8 (30.0–83.6) 0.68
FEV1 at time +12, average (95% CI) 56.7 (23.8–89.6) 55.1 (26.5–83.7) 0.83
FEV1 at time +24, average (95% CI) 59.8 (22.4–97.2) 53.2 (21.7–84.7) 0.48
Table 2: Variation of Shwachman and Crispin indexes during follow up
Erythrocyte mediated steroid therapy Ordinary therapy P value
Mean Shwachman index at enrolment (95% CI) 71.3 (36.2–106.4) 70.9 (41.3–100.5) 0.73
Mean Shwachman index at 12 months of follow up (95% CI) 62.6 (20.0–103.2) 68.4 (39.2–97.6) 0.68
Mean Shwachman index at 24 months of follow up (95% CI) 66.8 (21.9–111.7) 68.0 (37.6–98.4) 0.83
Mean Crispin index at enrollment (95% CI) 13.7 (4.5–22.6) 12.7 (5.3–20.1) 0.76
Mean Crispin index at 24 months of follow up (95% CI) 13.6 (5.2–22.0) 12.9 (5.9–19.9) 0.48BMC Pediatrics 2006, 6:17 http://www.biomedcentral.com/1471-2431/6/17
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ysis given the exploratory nature of this pilot study.
Inclusion of patients originally assigned to the experimen-
tal treatment would have resulted, however, in a much
smaller difference in FEV1 over time between the two
groups. The number of infective relapses that have
required antibiotic intravenous therapy, differently from
the previous study, was similar in the two groups,
although the average number of episodes was slightly
higher in the experimental therapy group. The absence of
blinding may be theoretically associated with a more strict
control of patients in the experimental group and with an
early recognition of infective relapses and, therefore, with
a timely treatment. The number of visits per month in the
experimental group was actually higher than in the stand-
ard treatment group.
Though the experimental therapy included in the study
may be useful for controlling chronic inflammation of the
airway in CF patients, additional preventive strategies
should be developed.
Conclusion
Although the number of enrolled patients in our study
was too low to draw definite conclusions, this new admin-
istration technique seems safe and moderately efficacious
despite the very low steroid circulating dose. The results
obtained by our study cannot be considered definitive but
may help planning an experimental, controlled, ran-
domised study which may give more robust results, and
may involve patients of different age groups with different
doses and administration schemes.
Based on means and standard deviations of FEV1
observed at 24 months in this study, a sample size of 150
patients per group would be sufficient for demonstrating
such a difference with a 95% confidence interval and a
power of 90%. If a clinical trial with a sufficient number
of participants will confirm these preliminary results, an
important therapeutic tool will be available to improve
the prognosis of CF patients. Moreover studies on corti-
costeroid drugs in CF paediatric patients need at least five
years to assess the control of inflammation in the long
term and the occurrence of late side effects. Alternative
strategies for inflammation control should focus on the
immune imbalance which has been found even in young
clinically stable CF patients [22].
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